Newron valuation report "A pivotal year"

Tuesday, March 26, 2024 @ 12:00 am

FY 2023 revenue surprised positively with a cash runway well into 2025, beyond major value inflection points. Substantial upside should be unlocked upon positive “Study 008A” results in non-TRS, a partnering deal with a CNS player and starting “Study 017” trial in TRS.

Key catalysts include:

Results “Study 008A” of evenamide in non-TRS (April 2024)
Partnering evenamide with a major CNS player (before starting “Study 017”)
Start pivotal “Study 017” trial of evenamide in TRS (Q3 2024)

Newron Valuation Report

You may also be interested in

Swiss Biotech Report 2024 shows sector performing well in 2023 by continuing to embrace international alliances

Record revenues of CHF 7.3 billion (USD 8.1 billion) – Capital investments increase by more than 50% to CHF 2 billion – CHF 1.4 billion by public companies, CHF 0.6 billion by private companies – Significant licensing and M&A activity in 2023 – VectivBio, T3, Vertex, Santhera – R&D investments of publicly traded biotech companies have decreased in line with global markets, wherea
April 23, 2024

Nouscom appoints Neil Gallagher as independent advisor

Dr. Gallagher, current President of R&D at Syndax Pharmaceuticals and former Chief Medical Officer and Head of Development at AbbVie, brings significant experience of end-to-end development that has resulted in the approval of multiple innovative medicines.
May 17, 2024

InSphero secures commercialization partnership with Genome Biologics

May 16, 2024

AC Immune and Takeda sign agreement for an Alzheimer immunotherapy

Takeda to receive exclusive option to license global rights to ACI-24.060, a potential first-in-class active immunotherapy designed to delay or slow Alzheimer’s disease progression AC Immune to receive upfront payment of $100 million upon closing and be eligible for an option exercise fee and additional potential milestones of up to approximately $2.1 billion AC Immune to host conference call an
May 13, 2024

Memo Therapeutics increases series C financing to CHF 45 million

Additional CHF 20 million raised from new investors Ysios Capital and Kurma Partners as well as from existing investors Proceeds will be used to expand Phase II of best-in-class anti-BK Virus antibody to become the largest study ever conducted for BK virus infection in kidney transplantation in kidney transplantation
May 7, 2024

Mabylon: Candidate nomination of an anti-allergen multispecific antibody for peanut allergy

In collaboration with Pfizer Ignite, Mabylon nominates its anti-allergen multispecific antibody product that is undergoing Investigative New Drug (IND)-enabling studies and subsequent clinical development for the treatment of peanut allergy.
May 10, 2024